In addition to CCN1, CCN2 targeting by monoclonal antibodies in CIA mice reduced the incidence and symptoms of RA, Th17 population and osteoclastogenesis, T cell proliferation and MMP3 activity (Nozawa et al. 2013; Nozawa 2014). The gene discussed is CCN2; the disease is rheumatoid arthritis.